PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2018

Albany, NY -- (SBWire) -- 09/27/2018 --DelveInsight has announced the addition of the "PD-1 & PDL-1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2018".The report provides comprehensive insights about marketed and pipeline drugs across this mechanism of action. It covers the marketed drug profiles, pipeline drug profiles including clinical and non-clinical stage products. The report also included global sales, analyst insights of the marketed drugs. The PD-1 & PDL-1 inhibitor market evolution and class share evaluation are also included. It also provides therapeutics assessment by therapy type, stage, administration route and molecule type. It further highlights the inactive pipeline products in this space.

PD-1 (programmed cell death protein 1) is found on the surface of cancer cells. It is used by tumors to evade the immune system so blocking its action enables the body to attack and kill cancer. T cells constantly monitor our body for abnormal cells, and eliminate them before they can turn into cancer. A key step in tumor development is in finding ways to avoid or shut down the immune system. When a T cell becomes activated, it also needs a stop signal in order to make sure it does not get over-activated. This can be done through inhibitory receptors, such as PD-1. After activation, T cells increase the expression of PD-1 on their surface, allowing them to receive a shutdown signal. Tumor cells take advantage of this system by expressing binding partners of PD-1, prematurely shutting down the T cells. Programmed death 1 (PD-1) proteins bind with two ligands, namely Programmed death-ligand 1 (PD-L1) and Programmed death-ligand 2 (PD-L2). Programmed death-ligand 1 (PD- L1) in humans is encoded by the CD274 gene. PD-L1 is also known as cluster of differentiation 274 (CD274). It is a 40 kDa type 1 transmembrane protein that plays a major role in suppressing the immune system during particular events such as pregnancy, tissue allograft, autoimmune disease and other disease states such as hepatitis. Normally the immune system reacts to foreign antigens where there is some accumulation in the lymph nodes or spleen which triggers a proliferation of antigen-specific CD8+ T cell. PD-L1 binds to its receptor, PD-1, found on activated T cells, B cells, and myeloid cells to modulate activation or inhibition.

According to some medical researchers, there could be some distinct differences between PD-1 and anti-PD-L1 inhibitors as they are not identical. They behave differently because they block different distinct sets of inhibitory interactions. In other words, PD-L1 inhibitors are monoclonal antibody that blocks the ligand side of the pathway expressed by the tumor cell.

PD-1 & PDL-1 Inhibitors Drug Companies:

1) Merck
2) Ono Pharmaceutical
3) Genentech
4) BeiGene
5) Innovent Biologics
And many others

Drugs covered

1)Keytruda
2)Opdivo
3)Atezolizumab
4)BGB-A317
5)IBI308
And many others

Request for sample pages : https://www.delveinsight.com/dev-sample.php?form_name=PD-1-and-PD-L1-Inhibitors---Competitive-Landscape,-Pipeline-and-Market-Analysis,-2018

Report Scope

1) The report builds understanding of the evolution of market share and class share evolution of PD-1 and PDL-1 inhibitors. The report also covers detailed information of marketed drugs with analyst insights, sales forecasting.
2) Coverage of overview including structure, mechanism, expression and mutation of PD-1 & PDL-1 inhibitors. The role PD-1 & PDL-1 inhibition in various pathological conditions.
3) Comprehensive insights into the pipeline products. The report provides detailed profiles of the pipeline assets and comparative analysis of clinical and non-clinical stage products. Inactive products are also part of the report.
4) Assessment of active pipeline assets segmented by stage, product type, route of administration, and molecule type.